AbbVie's Humira Tops NHS Drug Spend List
Executive Summary
A National Health Service spending report reveals the top 20 most expensive NICE approved drugs in England for 2016.
You may also be interested in...
New UK Cancer Drugs Fund Dismays Pharma, Charities
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation. Pharma companies believe they will have to shoulder additional financial risks while patients will still not get full access to the medicines they need.
Frustrated Roche Hopes NICE Will Eventually Back Kadcyla
Roche Holding AG hopes the UK's National Institute for Health and Care Excellence will continue seeking possible ways to provide the Swiss drug maker's breast cancer therapy Kadcyla (ado-trastuzumab emtansine) on the publicly-funded National Health Service despite rejecting it in final guidance on cost grounds.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.